舍托肝素钠(Certoparin sodium) - 药物靶点：factor Xa_在研适应症：肺栓塞，血栓栓塞，静脉血栓形成_专利_临床

An Open-label, Single Center, Parallel-group Study to Compare the Single- and Repeated-dose Pharmacokinetics of Stepwise Increasing Doses of Subcutaneous Certoparin (3000 IU o.d., 3000 IU b.i.d., 8000 IU o.d., and 8000 IU b.i.d.) in Subjects With Severe Renal Insufficiency and Healthy Subjects

This study will assess the pharmacokinetics in subjects with severe renal insufficiency and healthy subjects.

开始日期2011-12-01

申办/合作机构

Novartis Pharmaceuticals Corp.

NCT01179620 / Completed临床3期

A Multi-center, Prospective, Open-label, 8-weeks Study to Investigate the Efficacy, Safety and Pharmacokinetics of Certoparin (3000 IU Anti-Xa Bolus, With the Option to Titrate Dose)in the Prophylaxis of Clotting in the Extracorporeal Circuit in Patients Undergoing Chronic Hemodialysis

This study will assess the efficacy, safety and pharmacokinetics of certoparin when used to prevent clotting during hemodialysis.

开始日期2010-11-01

申办/合作机构

Novartis AG

EUCTR2010-019200-23-DE / Not yet recruitingN/A

A multi-center, prospective, open-label, 8-weeks study to investigate the efficacy, safety and pharmacokinetics of certoparin (3000 IU anti-Xa bolus, with the option to titrate dose) in the prophylaxis of clotting in the extracorporeal circuit in patients undergoing chronic hemodialysis

开始日期2010-07-01

申办/合作机构

Novartis Pharma GmbH

100 项与舍托肝素钠相关的临床结果

登录后查看更多信息

100 项与舍托肝素钠相关的转化医学

登录后查看更多信息

100 项与舍托肝素钠相关的专利（医药）

登录后查看更多信息

96

项与舍托肝素钠相关的文献（医药）

2021-01-01·Clinical and Applied Thrombosis/Hemostasis4区 · 医学

Prophylactic Anticoagulation With Intermediate-Dose Certoparin in Vascular-Risk Pregnancies—The PACER-VARP Registry

4区 · 医学

Article

作者: Güth, Martina ; Maier, Christiane ; Häge, Esther ; Grünewald, Martin ; Lehnert, Stephanie ; Bramlage, Peter ; Schimke, Alexandra

The management of pregnant women at increased risk of thromboembolic/other vascular events is still a matter of debate. In a single-center, retrospective, observational trial, we analyzed the safety and efficacy of prophylactic anticoagulation with certoparin in pregnant women at intermediate- or high-risk by EThIG criteria of thromboembolic/other vascular events. Subcutaneous certoparin 8,000 IU once daily was administered immediately after pregnancy confirmation and continued for 6 weeks postpartum. We investigated 74 pregnancies (49 women; mean age 31.8 years; weight 77.3 kg). Most prevalent risk factors were factor V Leiden mutation (40.5%), thrombogenic factor II mutation (12.2%) and protein S deficiency (8.1%). In 76 control pregnancies prior to registry inclusion/without anticoagulation there were 14 cases [18.4%] of venous thromboembolism (between week 7 gestation and week 8 postpartum); 63.2% pregnancies resulted in abortion (median week 8.6 gestation). With certoparin anticoagulation, thromboembolism was 1.4%, exclusively non-major bleeding was 4.1% and abortion was 10.8%. One case of pre-eclampsia necessitating obstetric intervention occurred. Prophylactic anticoagulation with intermediate-dose certoparin throughout pregnancies at increased venous vascular risk was safe and effective.

2020-11-01·DMW - Deutsche Medizinische Wochenschrift4区 · 医学

Plötzliche Belastungsdyspnoe bei einer jungen Frau – internistisch-gynäkologisches Grenzgebiet in der Notaufnahme

4区 · 医学

Article

作者: Lock, Guntram ; Mehl, Lisa ; Donner, Johanna

2019-01-01·Progress in Molecular Biology and Translational Science3区 · 生物学

Low molecular weight heparins and their clinical applications

3区 · 生物学

Review

作者: Hao, Cui ; Wang, Wei ; Sun, Mojian ; Wang, Hongmei ; Zhang, Lijuan

Heparin is an anticoagulant medication that was discovered in 1917 and used in clinic since 1935. Low molecular weight heparins (LMWHs) represent a refined use of heparin as anticoagulant medications that were developed in 1980s. LMWHs are obtained by cleaving heparin with different chemical or enzymatic methods. Eight chemically distinct and officially approved LMWHs are Bemiparin, Certoparin, Dalteparin, Enoxaparin, Nadroparin, Parnaparin, Reviparin, and Tinzaparin. LMWHs are mainly used for preventing blood clots, for treating deep vein thrombosis and pulmonary embolism, and for treating myocardial infarction. LMWHs have advantages over heparin in that they can be used at home with good predictability, dose-dependent plasma levels, a long half-life, less bleeding for a given antithrombotic even, smaller risk of osteoporosis in long-term use, and smaller risk of heparin-induced thrombocytopenia and thrombosis, a potential side effect of heparin. However, heparin is reversible with protamine sulfate while LMWHs have no antidote. Moreover, LMWHs have less of an effect on inhibiting thrombin activity than heparin. Furthermore, patients with end-stage renal diseases have to use heparin because LMWHs are dependent on functioning kidney for their clearance but heparin is primarily cleared in the liver. We will review the recent progress made on the clinically approved and under clinical trialed LMWHs and their potential medical applications. In particular, we will provide an update on the chemical characteristics and clinical use of different branded LMWHs. In addition, the potential clinical applications of LMWHs in other therapeutic area will also be discussed.

100 项与舍托肝素钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	舍托肝素钠	B01AB	DB09261

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肺栓塞	-	-	1997-01-01
血栓栓塞	-	-	1997-01-01
静脉血栓形成	-	-	1997-01-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肾功能不全	药物发现	匈牙利	Novartis Pharmaceuticals Corp.	2011-12-01
终末期肾脏病	药物发现	德国	Novartis Pharma AG	2010-11-01
尿毒症	药物发现	德国	Novartis Pharma AG	2010-11-01
血栓栓塞	药物发现	德国	Novartis AG	2007-01-01
栓塞	药物发现	德国	Novartis Pharma AG	2006-02-01
栓塞	药物发现	瑞士	Novartis Pharma AG	2006-02-01
心房颤动	药物发现	美国	Novartis AG	2005-04-01
心房颤动	药物发现	德国	Novartis AG	2005-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01179620 (Pubmed \| BMC Nephrol)	临床3期	维持	109	Certoparin	鹹選衊艱鹽鹹艱積簾鏇(蓋夢簾廠衊鹹繭糧鹽鬱) = 廠蓋構鏇淵獵簾積觸窪糧衊積鏇壓觸襯夢膚鬱 (顧窪餘鏇選壓鑰獵齋壓, 3.00 ~ 4.45) 更多	积极	2012-06-28
NCT00311753 (CERTAIN, Pubmed \| Expert Opin Pharmacother)	临床3期	-	342	Certoparin 3000 IU daily	(鹹製網齋鹹獵願夢鑰醖) = Major bleeding events occurred in three patients with UFH and one patient with certoparin 簾蓋遞醖構簾襯鏇蓋憲 (遞構餘膚願網鏇簾壓鏇 )	积极	2010-12-01
NCT00311753 (CERTAIN, Pubmed \| Expert Opin Pharmacother)	临床3期	-	342	UFH 7500 IU twice daily		积极	2010-12-01
NCT00171769 (Pubmed \| Clin Res Cardiol)	临床3期	心房颤动	203	Certoparin 8000 U anti-Xa	(簾膚襯繭遞鹽夢遞憲膚) = 餘願齋鹽襯艱夢夢艱窪襯膚鏇製構廠衊範範築 (顧膚鹹蓋廠簾淵鹹齋獵 ) 更多	-	2008-06-01